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Metastatic neuroendocrine prostate cancer (NEPC) is a highly aggressive
disease, whose incidence is rising. Long noncoding RNAs (lncRNAs) repre-
sent a large family of disease- and tissue-specific transcripts, most of which
are still functionally uncharacterized. Thus, we set out to identify the
highly conserved lncRNAs that play a central role in NEPC pathogenesis.
To this end, we performed transcriptomic analyses of donor-matched
patient-derived xenograft models (PDXs) with immunohistologic features
of prostate adenocarcinoma (AR+/PSA+) or NEPC (AR/SYN+/CHGA+)
and through differential expression analyses identified lncRNAs that were
upregulated upon neuroendocrine transdifferentiation. These genes were
prioritized for functional assessment based on the level of conservation in
vertebrates. Here, LINC00261 emerged as the top gene with over 3229-fold
upregulation in NEPC. Consistently, LINC00261 expression was signifi-
cantly upregulated in NEPC specimens in multiple patient cohorts. Knock-
down of LINC00261 in PC-3 cells dramatically attenuated its proliferative
and metastatic abilities, which are explained by parallel downregulation of
CBX2 and FOXA2 through distinct molecular mechanisms. In the cell
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cytoplasm, LINC00261 binds to and sequesters miR-8485 from targeting
the CBX2 mRNA, while inside the nucleus, LINC00261 functions as a
transcriptional scaffold to induce SMAD-driven expression of the FOXA2
gene. For the first time, these results demonstrate hyperactivation of the
LINC00261-CBX2-FOXA2 axes in NEPC to drive proliferation and metas-
tasis, and that LINC00261 may be utilized as a therapeutic target and a
biomarker for this incurable disease.
1. Introduction
Prostate cancer (PCa) is the most common male non-
cutaneous malignancy in the world, accounting for
more than 160 000 cases a year [1]. Metastatic PCa
accounts for around 6% of prostatic neoplasms at
diagnosis and is associated with worse prognosis [2].
Most metastatic PCa patients are diagnosed with
androgen-dependent (AD) disease, which is currently
treated with androgen-deprivation therapy (ADT) [3].
Despite treatment, 20–30% of patients will experience
progressive disease by developing castration-resistant
PCa (CRPC-Adeno). Mechanisms involved in this pro-
cess include the genetic amplification, or a gain-of-
function mutation of the androgen receptor (AR), as
well as activation of alternative signaling pathways,
most notably PI3K/AKT [4]. Patients with CRPC-
Adeno are treated with second-line hormonal and
chemotherapeutic regimens [5]. Unfortunately, these
second-line interventions only postpone further disease
progression. It has been reported that up to 50% of
CRPCs carry hallmarks of highly aggressive neuroen-
docrine PCa (NEPC) [6]. This phenotype may arise
from the transdifferentiation of neoplastic cells
exposed to hormonal therapy [7] and can be defined
by the expression of neuroendocrine markers such as
chromogranin A (CHGA), neural-specific enolase,
synaptophysin, and neural cell adhesion molecule-1.
Currently, NEPC therapy is limited to platinum-
based compounds, which may initially shrink the
tumor, but do not significantly increase survival [8].
NEPC poses several therapeutic challenges due to a
lack of AR expression, frequent metastatic events (par-
ticularly in visceral locations), and late diagnosis—
there are currently no effective biomarkers as NEPCs
do not secrete prostate-specific antigen (PSA). In 2017,
the median survival time for a patient diagnosed with
metastatic NEPC was 7 months [9]. Unfortunately, the
incidence of this disease is likely to rise due to the
widespread use of second-generation anti-androgen
therapeutics [4,10]; therefore, effective therapies are
urgently needed to target these cells.
Historically, cancer research has largely focused on
changes in protein expression and alterations in pro-
tein-coding regions, which comprise just 2% of the
human genome. A major portion of the genome com-
prises lncRNAs, which are defined as noncoding tran-
scripts longer than 200 bp. There are approximately
60 000 lncRNAs in the human genome [11], most of
which are functionally uncharacterized. lncRNAs are
often expressed at very low levels in human cells, but
some of these transcripts are more abundant and regu-
late important pathophysiological functions [12]. While
most lncRNAs are species-specific, a small fraction of
these transcripts is highly conserved and is thought to
regulate key cellular functions [13]. Some evolutionar-
ily conserved lncRNAs have been identified as master
regulators of cancer progression [13]. Here, we describe
for the first time a highly conserved lncRNA, long
intergenic nonprotein coding RNA 261 (LINC00261;
aka DEANR1; NC_000020.11), as a key driver of
NEPC proliferation and metastasis, respectively,
through regulation of chromobox 2 (CBX2) and fork-
head box A2 (FOXA2) expression. We delineate two
distinct mechanisms through which LINC00261 either
functions as a transcriptional scaffold for the FOXA2
gene in the nucleus or a micro-RNA (miRNA) sponge
for the CBX2 transcript in the cytoplasm.
2. Materials and methods
2.1. RNA-seq analysis of PDX models
RNA samples were isolated from patient-derived xeno-
graft models (PDXs) as previously described by Ref.
[14]. RNA sequencing (RNA-seq) and bioinformatic
analysis were carried out by the Centre for Genomics,
University of Liverpool. The resulting dataset was fur-
ther analyzed to determine lncRNAs differentially
expressed between hormone-sensitive prostatic adeno-
carcinoma (LTL-331) and NEPC (LTL-331R). Thresh-
olds for expression were set as log2 fold change
minimum 4; false discovery rate < 0.1; and fragments
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per kilobase of transcript per million mapped reads
(FPKM) greater than 10. Coding potential was
assessed using NCBI’s nucleotide BLAST (blast.ncbi.
nlm.nih.gov), Ensembl (http://www.ensembl.org), Cod-
ing Potential Calculator (http://cpc.cbi.pku.edu.cn),
and TestCode software (http://www.bioinformatics.
org/sms/testcode.html). The shortlist was then further
refined such that transcripts were ranked based on
evolutionary conservation using methods described in
Ref. [15].
2.2. RNA-seq analysis of LINC00261 knockdown
in PC-3 cells
RNA samples were isolated from PC-3 cells cultured
and treated with 10 nM small-interference RNAs (siR-
NAs) as described in Materials and methods for
siRNA reverse transfection. RNA-seq and bioinfor-
matic analysis were carried out by Molecular Pathol-
ogy Unit, Universit€atsspital Basel, Switzerland. The
resulting dataset was further analyzed to determine
differentially expressed transcripts between negative
control siRNA (NC) and LINC00261 siRNA (siRNA
1). Thresholds for expression were set as log2 fold
change above 2 (upregulated) and below 2 (downreg-
ulated).
2.3. cBioPortal analysis
Shortlisted lncRNAs were queried using cBioPortal
(http://www.cbioportal.org) to assess clinical relevance
and co-expression analysis. The datasets used for these
analyses are described in relevant figure legends. Data
were obtained from publicly available RNA-seq data-
sets and sorted by type of prostatic neoplasm [hor-
mone-naive (HN), CRPC, or NEPC].
In order to analyze copy number variations in
NEPC-associated pathways, LINC00261 and AKT sig-
naling pathway genes were queried. 17 AKT pathway-
associated genes were queried using cBioPortal’s
inbuilt ‘general PI3K-AKT-mTOR signaling’ query.
This included PIK3CA, PIK3R1, PIK3R2, PTEN,
PDPK1, AKT1, AKT2, FOXO1, FOXO3, MTOR,
RICTOR, TSC1, TSC2, RHEB, AKT1S1, RPTOR,
and MLST8. The dataset used for copy number analy-
sis was from the referenced study [16].
2.4. TANRIC analysis
The TANRIC analysis was carried out on shortlisted
lncRNAs (https://ibl.mdanderson.org/tanric/_design/ba
sic/query.html) to assess survival and to determine
associated mRNAs. lncRNAs were queried based on
their alias shown in Table S1, or by Ensembl ID, all
datasets were analyzed.
2.5. GEO profile data
Expression of LINC00261 in a panel of cell lines was
obtained from the NCI-60 cancer cell line panel (GEO
ID 86803759). Data were downloaded from https://
www.ncbi.nlm.nih.gov/geo/tools/profileGraph.cgi?ID=
GDS4296:228004_at and visualized using GRAPHPAD
PRISM 7 software (https://www.graphpad.com/scientific-
software/prism/).
2.6. LTL microarray analysis
The Living Tumour Laboratory data were obtained
from the gene expression database found at www.
livingtumourlab.com. Samples from HN, CRPC, and
NEPC tumors were used. Microarray data were down-
loaded from the PCa datasets and log2-transformed.
2.7. Cell culture
RWPE-1 cells were obtained from the American Tis-
sue Culture Collections (ATCC, Middlesex, UK) and
were cultured in keratinocyte serum-free media
(KSFM; Gibco, Loughborough, UK) supplemented
with 0.05 mgmL1 bovine pituitary extract (BPE) and
5 ngmL1 human recombinant epidermal growth fac-
tor (EGF) and 1% Pen-Strep (Gibco). LNCaP (clone
FGC), PC-3, and DU-145 cells were obtained from
ATCC and were cultured in RPMI-1640 (Gibco) sup-
plemented with heat-inactivated FBS (Gibco) and 1%
Pen-Strep (Gibco) for all assays but MTT assays
where phenol red-free media was used. Murine cell
lines T23 [17] and OPT7714 [18] were kindly provided
by Elena Jachetti and Mario P Colombo (Istituto
Nazionale Tumori, Milan, Italy) and were cultured in
Dulbecco’s Modified Eagle Medium (high-glucose;
Gibco), supplemented with 10% heat-inactivated GBS
(Gibco), 10 mM sodium pyruvate (Gibco), 10 mM
HEPES (Gibco), 2 mM L-glutamine (Gibco), and 1%
Pen-Strep (Gibco). All cells were cultured at 37 °C in
a humidified environment containing 5% CO2. Cells
prepared for in vivo work were transduced using con-
structs generated and packaged by Genecopoeia
(Rockville, MD, USA). PC-3 cells were transduced
using media supplemented with polybrene (aka hexadi-
methrine bromide; Sigma, Gillingham, Dorset, UK) at
a final concentration of 8 µgmL1. Cells were incu-
bated with purified human LINC00261 lentiviral parti-
cles overnight and were then washed with complete
media. 48–72 h post-transduction, stably transduced
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cells were isolated using puromycin selection (Gibco).
Selection was carried out for 2 weeks at a concentra-
tion of 1 µgmL1.
For inoculation of animals, the trypsinized cells
were washed 19 with PBS. The cells were counted
with an automated cell counter (TC20; Bio-Rad, Her-
cules, CA, USA) and resuspended at 107 cellsmL1 in
PBS for inoculation.
2.8. Analysis of gene expression
RNA was isolated from cells in culture using the RNeasy
Plus Mini Kit (Qiagen, Manchester, UK) according to
manufacturer’s instructions. Reverse transcription was car-
ried out using 1 lg RNA per reaction using the
High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Loughborough, UK) according to kit instruc-
tions. The resulting cDNA was diluted one in 10 for
RT-quantitative PCR (qPCR) analysis. cDNA panels of
non-neoplastic tissue were purchased from Clontech
(Saint-Germain-en-Laye, France). TaqMan probes were
used as stated in each experiment according to the manu-
facturer’s instruction. Human assays were obtained from
Thermo Fisher (Loughborough, UK): LINC00261
(Hs03679073_m1), LINC00491 (NEAR3) (Hs01374494),
LOC101929331 (NEAR5) (Hs04406674_m1),
LOC100507175 (NEAR8) (Hs01388460_m1), LINC01612
(NEAR16) (Hs04407222_m1), CTD-2151A2.1 (NEAR18)
(Hs04404647), LINC00616 (NEAR21) (Hs04232282_m1),
HPRT1 (Hs02800695), FOXA2 (Hs00232764_m1), and
CBX2 (hs01034268_m1). Murine assays were also obtained
from Thermo Fisher 9030622O22-Rik (Mm01335331_m1),
andHprt1 (Mm03024075_m1).
2.9. Localization of lncRNA
RNA was isolated from cells in culture in nuclear and
cytoplasmic fractions, which were separated using the
PARIS Kit (Ambion, Loughborough, UK) according
to manufacturer’s instruction. For validation and
localization studies, RT-qPCR was used with the
probes MALAT1 (Hs00273907_s1), GAPDH
(Hs02786624_g1), and HPRT1 (Hs02800695_m1).
2.10. siRNA reverse transfection
Knockdown studies were performed using the reverse
transfection method. Cells were seeded in a six-well or 96-
well plate with lipid:siRNA mixture prepared using Lipo-
fectamine 2000 (Invitrogen, Loughborough, UK) as per
manufacturer’s protocol. Final siRNA concentrations were
10 nmol. All dicer substrate short interfering RNAs
against LINC00261 were purchased from Integrated DNA
Technologies (Leuven, Belgium) [hs.Ri.LINC00261.13.1
(siRNA 1), hs.Ri.LINC00261.13.2 (siRNA 2), and hs.Ri.-
LINC00261.13.3 (siRNA 3)]. Control siRNAs were also
purchased from IDT (negative control DS NC1 and posi-
tive control HPRT-S1 DS). For murine cells, silencer select
siRNAs against 9030622O22-Rik were purchased (siRNA
1 = n404958, siRNA 2 = n440961, and siRNA
3 = n518634, as well as negative control; Thermo) and
transfected with 25 nM in the same manner previously
described. RNA was isolated using RNeasy Plus Mini Kit
(Qiagen).
2.11. MTT assays
Cells were plated in 96-well plates and treated with
siRNA as previously described. MTT assays were car-
ried out by first incubating with DMSO or media for
1 h. After this 5 mgmL1, thiazolyl blue tetrazolium
bromide (MTT; Sigma) was added at 10% of the well
volume. The cells were incubated with MTT for 3 h.
After this, all media were removed and MTT was solu-
bilized using 50 µL DMSO. The plate was then read
using a BMG OPTIMA POLARstar plate reader
(BMG Labtech, Aylesbury, UK) at 562 and 680 nm.
MTT assays were corroborated by manually cell
counting bright-field images of cultured cells.
2.12. Caspase 3/7 assays
Cells were plated in a white, flat-bottomed 96-well plates
and treated with siRNAs as previously described. On day
3 post-transfection, Caspase-Glo reagent was added per
well (Promega, Southampton, UK) according to manufac-
turer’s instruction, was added to well, and incubated for
1.5 h. Luminescence was then quantified using the BMG
POLARstar plate reader (BMG Labtech).
2.13. Wound-Healing assay (migration)
PC-3 cells were reverse-transfected for 18 h with
10 nmol siRNAs 2 and 3 as these did not yield a sig-
nificant reduction in viable cells as determined by
MTT assays.
After 18 h, a scratch was made in the cell mono-
layer using a sterile P20 pipette tip. Cells were imaged
periodically across the wound until the wound was
closed. Images were analyzed using the MRI wound-
healing tool, ImageJ.
2.14. Western blot
Cell lysates were created using 100 lL of RIPA buffer
[Tris pH 8.0 (Sigma); NaCl (Sigma); EDTA (Sigma);
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IGEPAL (Sigma); SDS (Sigma), NaF (Sigma); NaVO3
(Sigma)]. Protein was quantified using Pierce BCA assay
according to manufacturer’s protocol (Thermo). Ten
microgram of protein was resolved by gel electrophoresis
on reducing SDS/PAGE (Tris/glycine 4–20%, Thermo)
run at 125 V for 2 h. The proteins were then transferred
to nitrocellulose membrane at 350 Ma for 1.5 h. The
membranes were blocked in 5% nonfat milk dissolved in
Tris-buffered saline (TBS; Sigma) at room temperature for
1 h. Following this, blots were incubated overnight at
4 °C with protein-specific primary antibodies in 5% milk
in TBS supplemented with 2% Tween-20 (Sigma). Anti-
bodies used were RabMab anti-FOXA2 (Ab108422;
Abcam, Cambridge, UK) and RabMab anti-HPRT1
(ab133242, Abcam). After incubation, blots were washed
five times in TBS-T for 10 min each. Lastly, blots were
incubated with HRP-conjugated anti-mouse secondary
antibody diluted in 10 mL of TBS-T at room temperature
for 1 h [goat anti-rabbit IgG (Sigma)]. After washing as
above, ECL Western Blotting Substrate Kit was used
(Millipore, Watford, UK) and blots were visualized using
Syngene Gbox with GENETOOLS software (Syngene, Banga-
lore, India).
2.15. Clinical sample analysis (FFPE RNA
isolation)
Patient tissue was obtained in the form of FFPE blocks
from the Royal Surrey County Hospital, in Guildford,
UK. All patients had histologically proven PCa and had
failed at least three lines of conventional therapies.
Patients consented to the evaluation of their tissue, and
their study was approved by the local ethics committee ref.
12/LO/1661. NEPC samples were defined histologically as
having at least moderate expression of one of the following
markers SYP, ENO2, and CHGA. AD samples were
defined histologically and having expression of AR and/or
PSA, and being negative for NE markers. FFPE blocks
were obtained from the University of Surrey. RNA was
isolated from the FFPE blocks using the RecoverAll
Extraction Kit (Thermo). For each sample, an average of
800 ng of total RNA was reverse-transcribed using the
SuperScript VILO cDNA Synthesis Kit (Thermo). RNA
isolation and cDNA synthesis were performed in the Con-
tract R&D Unit of the Institute of Pathology and Medical
Genetics of Basel. The resulting cDNA was used for
qPCR analysis of LINC00261 and HPRT1 using the Taq-
Man probes described previously.
2.16. RNA immunoprecipitation assay
An RNA-binding protein immunoprecipitation (RIP)
assay was performed using the Magna RIP Kit
(Millipore) according to manufacturer’s instruction.
Cell lysates from 10 9 106 cells and 2–5 µg of control
IgG or antibody against SMAD2/3 (R&D Systems;
AF3797, Abingdon, UK) were used. We validated the
RIP assay using the SNRNP70 antibody, which can
bind to U1 snRNA. A ChIP assay was performed
using magnetic beads. Equal amounts of chromatin
for each sample and 1 µg of control IgG or antibody
against SMAD2/3 were used.
2.17. Animal study
Immunocompromised mice (NOD.Cg-Rag1tm1Mom
Il2rgtm1Wjl/SzJ) were purchased from the Animal
Resources Centre at BC Cancer Research Centre. All
procedures performed were approved by the Animal
Care Committee at the University of British Columbia
(Certificate # A16-0304). Six-week-old mice were inoc-
ulated with PC-3-NC (nontargeting shRNA knock-
down) or shLINC00261 (LINC00261KD) cells at both
left and right flanks. Each flank was inoculated with
106 viable cancer cells, accurately counted using the
trypan blue counter viability stain. Four mice were
inoculated with each cell line; therefore, there were
eight inoculation sites per cell line. The mice were
monitored twice per week for palpable tumor and/or
tumor measurement, and the monitoring was started
1 week after cell inoculation. Dimensions of tumors
were measured with a caliper, and the tumor volume
was calculated with the formula: tumor volume
(mm3) = 0.523 9 length (mm) 9 width2 (mm2).
2.18. Zebrafish embryo metastasis assessment
Wild-type ABTL zebrafish were maintained in aquaria
according to standard protocols. Embryos were gener-
ated by natural pairwise mating and raised at 28.5 °C
on a 14-h light/10-h dark cycle in a 100-mm Petri dish
containing aquarium water with methylene blue to pre-
vent fungal growth. All experiments were performed
with 2- to 7-day-old embryos postfertilization and were
done in approved University of Michigan fish facilities
using protocols approved by the University of Michi-
gan Institutional Animal Care and Use Committee
(UM-IACUC). Cell injections were carried out as pre-
viously described [19]. In brief, GFP-expressing NC-
treated, si LINC00261-treated, or siFOXA2-treated
PC-3 cells were resuspended in PBS at the concentra-
tion of 1 9 107 cellsmL1. Forty-eight hours after fer-
tilization, wild-type embryos were dechorionated and
anesthetized with 0.04 mgmL1 tricaine. Approxi-
mately 10 nL (approximately 100 cancer cells) was
microinjected into the perivitelline space using a
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borosilliac micropipette tip with filament. Embryos
were returned to aquarium water and washed twice to
remove tricaine, and then moved to a 96-well plate
with one embryo per well and kept at 35 °C for the
duration of the experiment. All embryos were imaged
at 24-h intervals to follow metastatic dissemination of
injection cells. Water was changed daily to fresh
aquarium water. More than 30 fish were injected for
each condition (wild-type no. 2, n = 30; wild-type no.
5, n = 50; wild-type no. 57, n = 35; wild-type no. 84,
n = 57; wild-type no. 113, n = 38), and metastasis was
visually assessed daily up to 5 days after injection (i.e.,
for a total of 7 days postfertilization) by counting the
total number of distinct cellular foci in the body of the
embryos. All of the metastasis studies were terminated
at 7 days postfertilization in accordance with the
approved embryo protocols. Embryos were either
imaged directly in the 96-well plates or placed onto a
concave glass slide to capture representative images
using a fluorescent microscope (Olympus IX71). For
quantification, evidently distinct cell foci in the embryo
body were counted 72 h after the injections.
2.19. miR mimic and inhibitor studies
PC-3 cells were reverse-transfected with 30 nM NC or
miR-8485 inhibitor/mimic using the method previously
described. The sequences used were obtained from
Thermo Fisher and were as follows: miR-8485 inhibi-
tor (NH31809); miR-8485 mimic (MC31809); NC inhi-
bitor (4464076); and NC mimic (4464058).
2.20. Analysis of miR expression
For miRNA analysis, RNA was isolated using miR-
Neasy (Qiagen, Manchester, UK) according to manu-
facturer’s instructions. Reverse transcription was
carried out using the miRNA cDNA Synthesis Kit
(Applied Biosystems, Loughborough, UK) according
to kit instructions using the reverse transcription pri-
mers provided with miR-8485 (480631_mir), or U6
snRNA (001973) using 10 ng RNA per reaction. The
resulting cDNA was diluted 1 in 10 for RT-qPCR
analysis using the qPCR TaqMan probes provided in
the kits described for miR-8485 or U6 according to
manufacturer’s instructions.
2.21. miRNA-binding dual-luciferase reporter
assay
For the miRNA-binding assay, a 100-bp segment cen-
tered at the miR-8485 seed sequence (50-
GTATGTGTGTGCGTGTGTGTTT-30) in 30UTR of
LINC00261 was cloned into the firefly luciferase gene
using the pmirGLO dual-reporter system (Promega;
E1330). For the control vector, the same LINC00261
segment with the seed sequence replaced with a ran-
dom sequence (50-GTATGTCCATGAAGC-
CATTGTC-30) was cloned into the luciferase gene.
Cloning was performed using the NheI-HF (NEB;
R3131L) and AccI (NEB; R0161S) restriction enzymes
following the manufacturer’s instructions. Cloned
sequences were verified through the Sanger sequencing.
A total of 4 9 106 HEK293FT cells were seeded in 10-
cm dishes and transfected the next day with 10 lg of
either unmodified pmirGLO vector or vectors encod-
ing the LINC 00261 or the mutant-LINC00261
sequences. After 10 h, the transfected cells were plated
into Poly-D-lysine 12-well plates at 400 000 cells per
well and transfected with 25 or 50 nM of mirVana
miRNA mimic negative control #1 (Thermo Fisher
Scientific; 4464058) or has-miR-8485 (Thermo Fisher
Scientific; Cat. No. 4464066; miRBase Accession No.
MIMAT0033692). After 48 h, cells were lysed using
100 lL of passive lysis buffer for 5 min at room tem-
perature followed by two rounds of freeze–thaw cycles
and were centrifuged at 4 °C for 10 min at max speed
(> 10 000 g). The supernatant was then diluted 1/5 or
1/10, and dual-luciferase activity was recorded as per
manufacturer’s protocol (Promega; E2920) using the
TECAN Infinite M1000 Pro Plate Reader, with each
condition having 3–6 independent replicates. The plate
reader was set to automatic attenuation with 1000-ms
integration time. Cell number variation and/or differ-
ences in transfection efficiencies were controlled by
normalizing the firefly luciferase signals with the
matched Renilla luciferase signals. The firefly-to-
Renilla ratios values were then normalized using sig-
nals from the unmodified pmirGLO-treated cells to
control for any off-target binding of the miR-8485 to
the luciferase transcripts.
2.22. Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue sections were
prepared, and histopathologic and immunohistochemi-
cal analyses were performed as previously described
[20]. IHC staining was carried out using anti-Ki67
(Thermo Fisher, RM-9106, 1 : 100). Biotinylated
secondary antibody (Vector Laboratories) peroxidase-
linked avidin/biotin complex reagents (Vector Labora-
tories) and diaminobenzidine (DAB, Sigma-Aldrich)
were used for the staining. Sections were imaged using
10X objective of Microphot-fx (Nikon) using Surveyor
software (Objective Imaging). The percent staining per
section of Ki67 was evaluated using IMAGEJ by setting
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a threshold and analyzing particles. Five random areas
were analyzed per section.
2.23. Overexpression of LINC00261 in DU-145
cells
LINC00261 open reading frame-encoding plasmids
were kindly provided by the laboratory of Dr Crystal
Marconett and were previously described [21]. DU-145
cells were maintained as previously described before
being transfected with either an empty vector or
LINC00261 plasmids using Lipofectamine 3000
(Thermo Fisher) using 2.5 µg DNA for 72 h according
to manufacturer’s instructions.
2.24. In silico prediction of miRNA target genes
In silico predictions for miRNA-lncRNA-binding site
were carried out with the online open-access lncBase
v.2 database (http://carolina.imis.athena-innovation.gr/
diana_tools/web/index.php?r=site%2Ftools). Pre-
dicted miRNAs are ranked based on probability of
their binding in a previously published DIANA-
LncBase v2 database [22]. LncBase v.2 scores predicted
miRNA targets based on preset parameters and
assigned a score to the predicted miRNA and used it
to rank them on the screen. The table shown in the
figure are the different types of bindings predicted by
the database. Top-ranked miRNA was selected for fur-
ther study. Prediction for miRNA–mRNA interactions
was investigated using four different independent
online, open-access databases (TargetScan, RNA22,
mirDB, and miRWalk). Predicted target mRNAs were
overlapped with genes downregulated upon
LINC00261 knockdown (RNA-seq) in PC-3 cells. Top
ranking mRNAs were prioritized for functional valida-
tion. Direct links to the databases are included below:
TargetScan (http://www.targetscan.org/vert_72/);
RNA22 (https://cm.jefferson.edu/rna22/); mirDB
(http://mirdb.org/); and miRWalk (http://mirwalk.
umm.uni-heidelberg.de/).
2.25. ChIP-seq and data analysis
ChIP experiments were carried out using the High-
Cell# ChIP-Protein G Kit (Diagenode) as per the man-
ufacturer’s protocol. Chromatin from five million cells
was used per ChIP reaction with 10 lg of the
SMAD2/3 protein antibody (Abcam: ab202445). In
brief, cells were trypsinized and washed twice with 19
PBS, followed by crosslinking for 8 min in 1%
formaldehyde solution. Crosslinking was terminated
by the addition of 1/10 volume 1.25 M glycine for
5 min at room temperature followed by cell lysis and
sonication (Bioruptor, Diagenode), resulting in an
average chromatin fragment size of 200 bp. Frag-
mented chromatin was then used for immunoprecipita-
tion using various antibodies, with overnight
incubation at 4 °C. ChIP DNA was de-crosslinked
and purified using the iPure Kit V2 (Diagenode) using
the standard protocol. Purified DNA was then pre-
pared for sequencing as per the manufacturer’s instruc-
tions (Illumina). ChIP samples (1–10 ng) were
converted to blunt-ended fragments using T4 DNA
polymerase, Escherichia coli DNA polymerase I large
fragment (Klenow polymerase), and T4 polynucleotide
kinase [New England BioLabs (NEB)]. A single A base
was added to fragment ends by Klenow fragment (30–50
exo minus; NEB) followed by ligation of Illumina
adaptors (Quick ligase; NEB). The adaptor-ligated
DNA fragments were enriched by PCR using the Illu-
mina barcode primers and Phusion DNA polymerase
(NEB). PCR products were size-selected using 3%
NuSieve Agarose Gels (Lonza) followed by gel extrac-
tion using QIAEX II reagents (Qiagen). Libraries were
quantified and quality-checked using the Bioanalyzer
2100 (Agilent) and sequenced on the Illumina HiSeq
2500 Sequencer (125-nucleotide read length).
Paired-end, 125-bp reads were trimmed and aligned
to the human reference genome (GRC h38/hg38) with
the Burrows–Wheeler Aligner (BWA 0.7.17-r1198).
The SAM file obtained after alignment was converted
into BAM format using SAMTOOLS (Version: 1.9).
MACS2 callpeak was used for performing peaking
calling with the following option: ‘macs2 callpeak–call-
summits–verbose 3 -g hs -f BAM -n OUT–qvalue
0.05’. For H3K27ac data—broad option was used.
Using deepTools bamCoverage, a coverage file
(bigWig format) for each sample was created. The cov-
erage is calculated as the number of reads per bin,
where bins are short consecutive counting windows.
While creating the coverage file, the data were normal-
ized with respect to each library size. ChIP peak pro-
file plots and read-density heat maps were generated
using deepTools, and cistrome analyses were carried
out using the ChIPpeakAnno or ChIPseeker packages
in R.
2.26. Soft agar colony formation assay
PC-3 cells were first treated with either 50 nM of non-
targeting control siRNA or siRNA targeting the
LINC00261 or FOXA2 transcripts using the RNAi-
MAX reagent as described above. Twenty-four hours
after siRNA transfections, 5000 or 10 000 viable PC-3
cells were layered in 1 mL of 0.3% Noble agar
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(Sigma-Aldrich; CAS Number 9002-18-0) over an
already solidified layer of 0.6% Noble agar per well of
a six-well plate, with 200 lL of complete media on the
top to prevent desiccation. The cells were then allowed
to form colonies for 14 days with media being replen-
ished every 3 days, after which they were stained with
iodonitrotetrazolium chloride (Sigma-Aldrich; CAS
Number 146-68-9) and imaged using a scanner. Dis-
tinct individual colonies were manually counted from
three randomly chosen 109 fields per well and aver-
aged. This assay was carried out at least two times
with two replicates per condition per experiment.
2.27. Ethical approval statements
FFPE samples were obtained from the University of
Surrey. Patients consented to the evaluation of their
tissue, and their study was approved by the local ethics
committee reference 12/LO/1661. All murine proce-
dures performed were approved by the Animal Care
Committee at the University of British Columbia (Cer-
tificate # A16-0304). Animals were housed in a certi-
fied animal facility at the British Columbia Cancer
Research Centre—Animal Resource Centre (Vancou-
ver, Canada) following all ethical housing procedures
and daily weekday monitoring. PDXs were maintained
by transplantation into subrenal capsules of male non-
obese diabetic/severe combined immunodeficiency
(NOD-SCID) mice as previously described (Lin et al.
[20]). All animal experiments were performed following
the ethical guidelines and standards set by the Declara-
tion of Helsinki and in accordance with the established
animal care and use protocols approved by the UBC
Animal Care Committee (protocol #: A10-0100). All
zebrafish procedures were carried out in approved
University of Michigan fish facilities using protocols
approved by the University of Michigan Institutional
Animal Care and Use Committee (UM-IACUC).
3. Results
Using previously described high-fidelity patient-derived
xenograft (PDX) models [20], we sought to identify
lncRNAs that could be functionally implicated in
NEPC pathogenesis. Using RNA-seq, we profiled tran-
scriptomes of a well-studied, donor-matched PDX pair
that show divergent histopathologic features: LTL-331
(resembles prostate adenocarcinoma) and LTL-331R
(resembles NEPC). Differential expression analyses
between LTL-331R vs LTL-331 revealed that out of
the 15 224 identified lncRNAs, only 32 genes were
upregulated in the neuroendocrine model that met our
stringent criteria of log2 fold change ≥ 4, FDR < 0.01,
and FPKM > 10. Second-pass filtering using Coding
Potential Calculator (http://cpc.cbi.pku.edu.cn/) and
TestCode (https://www.bioinformatics.org/sms/testc
ode.html) software yielded the final list of 26 bona fide
lncRNAs, which were then ranked by level of conser-
vation depending on the number of orthologs in 17
species (16 vertebrates and one invertebrate) as previ-
ously described [15] (Fig. S1A). Here, LINC00261
emerged as the most conserved gene with marked
upregulation in the neuroendocrine disease (Fig. S1B).
Notably, using TaqMan qPCR we were able to con-
firm over 3229-fold overexpression of LINC00261 in
LTL-331R vs LTL-331 (Fig. 1A), and additionally val-
idated three other nominated transcripts for which a
predesigned TaqMan probe was available.
3.1. LINC00261 is selectively upregulated in
human specimens of NEPC
To assess whether our RNA-seq results could be gen-
eralized, we investigated the expression of LINC00261
in other biologically independent PDX models from
the Living Tumour Laboratory (http://www.livingtu
morlab.com/). We found LINC00261 to be signifi-
cantly upregulated in four NEPC PDX tumor lines
compared with 13 hormone-na€ıve tumor lines
(P = 0.0102; Fig. 1B). These results were further cor-
roborated using an in-laboratory patient biopsy cohort
comprising of 8 adenocarcinomas and 11 NEPC for-
malin-fixed specimens, where LINC00261 expression
(qPCR) was elevated in the neuroendocrine samples
(P = 0.0387; Fig. 1C).
Next, we investigated whether LINC00261 expres-
sion could distinguish between CRPC-Adeno and
NEPC using a publically available patient database
[16], which includes genomic and transcriptomic data
from 34 CRPC and 15 NEPC tumors. Again,
LINC00261 had a significantly higher expression in
NEPC patients by 161-fold compared with CRPC-
Adeno patients (P = 0.0003; Fig. 1D). Using the same
clinical dataset, we explored whether LINC00261 is
associated with other markers of neuroendocrine dis-
ease (Table S1). Our analysis revealed a very signifi-
cant correlation between LINC00261 and CHGA,
ENO2, CBX5, and NCAM-1 (Table S1). Notably,
LINC00261 expression was negatively correlated with
AR amplification (P = 0.0025; Fig. 1E), but positively
correlated with AKT2 amplification (P = 0.0197;
Fig. 1F). LINC00261 expression was also significantly
upregulated in metastatic PCa lesions from the liver as
opposed to other sites (Fig. 1G), which often show
neuroendocrine features [23]. Taken together, these
results show that LINC00261 is selectively upregulated
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in human NEPC relative to both hormone-sensitive
and hormone-independent adenocarcinomas, where its
expression is positively associated with classical neu-
roendocrine markers.
3.2. LINC00261 is required for survival and
invasiveness of NEPC
First, using qPCR we profiled the expression of
LINC00261 in a panel of human prostate cell lines:
RWPE-1 (non-neoplastic); LNCaP (AR mutant, hor-
mone-sensitive PCa); DU-145 (AR-negative); H660
and PC-3 (NEPC models that are AR-negative and
express NE markers [7,24]). Consistent with the clini-
cal findings, LINC00261 was highly upregulated in the
neuroendocrine H660 (227-fold vs RWPE-1) and PC-3
cells (2714-fold vs. RWPE-1, Fig. 2A), compared with
both normal prostate and AR-positive PCa cells.
Next, subcellular fractionation was followed by qPCR,
using a nuclear-retained lncRNA (MALAT1) and a
A B C D
E F G
PDX models Biopsy samples Paent ssue
Fig. 1. LINC00261 is associated with NEPC. (A) Expression of (TaqMan qPCR) of select lincRNAs that are upregulated in NEPC in the LTL-
331/331R PDX model. (B) Relative expression (microarray) of LINC00261 in several PDX models of prostate adenocarcinoma (n = 13) and
NEPC (n = 4) from the Living Tumor Laboratory. (C) Relative expression (qPCR) of LINC00261 in FFPE biopsy samples from NEPC (n = 11)
and CRPC-Adeno (n = 8) patients. (D) Expression of LINC00261 (RNA-seq) in patient specimens with features of neuroendocrine (n = 15) or
castration-resistant (n = 34) disease. Datasets used is from Ref. (Barbieri et al. [54]; Beltran et al. [16]) (E) LINC00261 expression in patient
samples with or without AR copy gains (**P = 0.0025), or (F) AKT2 copy gains, an activating component of the PI3K/AKT pathway
(*P = 0.0197). (G) LINC00261 expression in clinical PCa biopsies from secondary lesions in the prostate/lymph nodes (n = 25), bone
(n = 29), or liver (n = 17; ***P < 0.001, ANOVA and Tukey’s post hoc test). Data from cBioPortal, Metastatic PCa SU2C/PCF Dream Team
Cell, 2015. Data in B–E were analyzed by two-tailed unpaired t-test. All data are presented as mean  SEM with at least two independent
biological replicates.
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mRNA (GAPDH) as controls, as previously described
[25–27]. This experiment revealed roughly 80% of the
transcript to be cytoplasmic, while the rest localized
within the nucleus (Fig. 2B). Given the high conserva-
tion of LINC00261, we also profiled the expression of
its murine ortholog 9030622O22-Rik in cell lines
derived from murine PCa [17,18]. Our results showed
a dramatic upregulation of 9030622O22-Rik in
OPT7714 cells (NEPC) by 120-fold compared with
T23 cells (adenocarcinoma; Fig. S2A); and in
OPT7714, the transcript was equally abundant in the
cytoplasmic and nuclear compartments (Fig. S2B)
This suggests that both expression and cellular local-
ization of LINC00261 are conserved between human
and murine NEPC cells.
Given the highest expression of LINC00261 in PC-3
cells, we selected this cell line for the functional stud-
ies. We first validated three distinct siRNAs targeting
LINC00261. With only 10 nM treatment of individual
siRNAs, we achieved 50–75% knockdown efficiency
within 48h after transfection relative to the control,
nontargeting siRNA-treated cells (Fig. S2C). Notably,
knockdown of LINC00261 in PC-3 cells dramatically
attenuated their proliferative ability starting from day
3 (Fig. 2C). At this time point, under the microscope,
LINC00261-silenced cells showed evident morphologi-
cal signs of apoptosis (cell shrinkage, membrane bleb-
bing, etc.; Fig. S2D) and reduced number of viable
cells (Fig. S2E), which we confirmed using the caspase













So-agar colony formaon assay
(PC3 cells at 14 days)
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Fig. 2. LINC00261 is required for NEPC cell viability and invasiveness. (A) Expression (qPCR) of LINC00261 in a panel of prostate cell lines.
(B) Subcellular localization of LINC00261, GAPDH, and MALAT1 RNA transcripts in PC-3 cells. (C) Viability (MTT assay) of PC-3 cells treated
with a control, nontargeting siRNA (siNC), or distinct siRNAs targeting LINC00261 at 10 nM dosage. (D) Cell viability-adjusted activity of
caspase 3/7 after 72 h of siRNA-mediated LINC00261 knockdown in PC-3 cells. (E) Left, Representative images of iodonitrotetrazolium
chloride stained soft agar PC-3 cell colonies after treatment with either the nontargeting, control siRNA (siNC), or siRNA targeting the
LINC00261 (siLINC00261) transcript (two-tailed t-test). Right, Average number of soft agar colonies per 109 field of siNC- or siLINC00261-
treated PC-3 cells. The scale bar at the bottom marks a 10 lm width. Distinct cells colonies were counted from three randomly chosen 10X
field per well from two biological replicates. All data are presented as mean  SEM with at least two independent biological replicates. (C)
Analyzed using two-way ANOVA with Tukey’s multiple comparisons test. (D) Analyzed by one-way ANOVA with Dunnett’s post hoc test.
(E) Analyzed by two-tailed t-test. *P < 0.05; ****P < 0.001.
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distinct siRNAs in PC-3 cells resulted in significant
activation of the executioner caspases 3/7 that irre-
versibly commits the cells to death via apoptosis
(siLINC00261 No. 1 P = 0.0001; siLINC00261 No. 2
P = 0.0036; Fig. 2D). Notably, knockdown of
LINC00261 in non-neoplastic RWPE-1 cells did not
significantly affect cell growth or induce caspase 3/7
activation (Fig. 2D). Conversely, overexpression of
LINC00261 in DU-145 cells induced a significant
increase in cellular growth, compared with cells
expressing the empty control vector (P = 0.003;
Fig. S2F).
Since NEPC is characterized by an elevated meta-
static rate, we decided to investigate the effects of
LINC00261 silencing on migration and anchorage-in-
dependent growth. We transiently treated PC-3 cells
with distinct siRNAs for 18h and assessed their migra-
tory abilities using the scratch wound-healing assay or
their invasive abilities using the Boyden chamber
assay. Importantly, within 18h we were able to achieve
greater than 60% target knockdown (Fig. S3A) and
had no impact on cell viability (Fig. S3B). While we
found no changes in the migration ability (Fig. S3C,
D), LINC00261 knockdown significantly attenuated
the ability of PC-3 cells to form colonies in soft agar
relative to the control cells (P = 0.0006; Fig. 2E).
Taken together, these results demonstrate that
LINC00261 is required to maintain the hyperprolifera-
tive and anchorage-independent survival of NEPC
cells, which are two defining pathologic features of this
disease.
3.3. LINC00261 is required for the proliferation of
NEPC cells in vivo
Our experiments so far indicate that LINC00261 pro-
motes the proliferation and invasion of NEPC cells.
To corroborate these findings in vivo, we generated
PC-3 cells with stable knockdown of LINC00261
using a lentiviral shRNA system. After drug selection,
we confirmed LINC00261 knockdown in
shLINC00261-treated cells (Fig. 3A) and, after a few
passages, injected an equal number of viable
shLINC00261 and shControl PC-3 cells into both
dorsal flanks of immunocompromised mice. Tumor
growth was monitored twice per week for up to
32 days as previously described [28]. Notably, the
median time to the formation of palpable tumors in
individual mice was significantly delayed in
shLINC00261 vs shControl-treated PC-3 cells (log-
rank test: P = 0.018; Fig. 3B). After 32 days of
growth, the average tumor weight was significantly
smaller in shLINC00261 relative to the control group
(P = 0.0043; Fig 3C). Most notably, consistent with
our in vitro data, the reduction in tumor weights was
accompanied by a marked reduction in the levels of
the proliferation marker Ki67 in the shLINC00261
tumors (Fig. 3D,E). Taken together, these data
strongly corroborate the functional requirement of
LINC00261 to sustain NEPC cell proliferation in a
physiologically relevant in vivo system.
3.4. Nuclear LINC00261 promotes cell invasion
by regulating FOXA2 expression
As most lncRNAs work with cognate protein partners
to have a functional effect, we interrogated the TAN-
RIC database [29] to identify protein-coding genes
associated with LINC00261 expression in patient
tumors. We found FOXA2 to be the most significantly
co-expressed gene with LINC00261 (Spearman’s corre-
lation = 0.82; Fig. 4A). This positive transcriptional
correlation was evident even in other cancers
(Table S2), and in normal tissues, both LINC00261
and FOXA2 were highly co-expressed in endoderm-
derived organs (Fig. S4A,B). Concordant with the
clinical expression profile of LINC00261, FOXA2
expression was significantly elevated in NEPC PDX
models (Fig. 4B) and NEPC patient tumors (Fig. 4C)
compared with prostate adenocarcinoma. FOXA2
expression was also significantly elevated in metastatic
PCa lesions from the liver (Fig. S4C). Intriguingly,
after castration in mice bearing the LTL-331 tumor
line, FOXA2 expression was followed by the upregula-
tion of LINC00261, peaking at about 12wks, as the
tumor cells transdifferentiate into the neuroendocrine
LTL-331R tumor line (Fig. S4D). This is accompanied
by specific activation of FOXA2 target genes in LTL-
331R (Fig. S4E). LINC00261 is coded just 2.4 kb
downstream of FOXA2 on chromosome 20, and a
recent study showed LINC00261 to physically recruit
SMAD2/3 to the FOXA2 promoter coded in cis [30].
Thus, we set to validate whether a similar mechanism
couples together the expression of LINC00261 and
FOXA2 in NEPC cells.
Firstly, we knocked down LINC00261 in PC-3 cells
and found a parallel downregulation in both the
mRNA (Fig. 4D) and protein abundance of FOXA2
(Fig. 4E). Interestingly, we found 9030622O22-RiK to
similarly regulate Foxa2 expression in the murine
NEPC cell line OPT7714 (Fig. 4E). Next, we per-
formed RNA co-immunoprecipitation (RIP) assays
using an anti-SMAD2/3 or IgG control antibody in
PC-3 cells. Using qPCR, we detected a specific and
dramatic (> 12-fold) co-enrichment of LINC00261
upon SMAD2/3 immunoprecipitation relative to the
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IgG control (Fig. 4F, P < 0.0001). In ChIP followed
by sequencing (ChIP-seq) assay, LINC00261 knock-
down triggered a marked decrease in the chromatin
binding of the SMAD2/3 transcriptional complex
(Fig. 4G, Fig. S5A), including SMAD2/3 binding at
cis-regulatory elements of the FOXA2 gene and bona
fide TGF-b1/SMAD target genes, namely ROR1,
SKIL, and SPTLC3 (Fig. S5A,B). Thus, LINC00261
regulates FOXA2 mRNA expression by recruiting the
SMAD transcriptional machinery to the cis-regulatory
elements of the FOXA2 gene in NEPC cells, which is
consistent with previous reports describing SMAD-me-
diated regulation of FOXA2 expression in other cell
lineages [30–32].
This prompted a related question: Which oncogenic
functions of LINC00261 are mediated through
FOXA2? To address this, using siRNAs we knocked
down FOXA2 expression in PC-3 cells and assessed
the impact on proliferation and invasion. While
knockdown of FOXA2 had no effect on cellular prolif-
eration, it dramatically attenuated the ability of PC-3
cells for anchorage-independent growth in the soft
agar colony formation assay (Fig. S5C). It also dra-
matically attenuated the metastatic spread of PC-3
cells in zebrafish embryos. In this assay, we treated
RFP-labeled PC-3 cells with a control or FOXA2 or
LINC00261 targeting siRNA and injected equal num-
ber of viable cells into the perivitelline space of zebra-
fish embryos at 2 days postfertilization (n > 40 in each
group) as previously described [33]. Injected embryos
were monitored for invasion and spread of PC-3 cells
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Fig. 3. LINC00261 silencing in vivo delays tumor formation. (A) LINC00261 expression (qPCR) in PC-3 cells stably expressing a nontargeting
control (shControl) or shRNA targeting LINC00261 (P < 0.0001). (B) Kaplan–Meier analysis for tumor formation in mice injected with cancer
cells expressing shLINC00261 or shControl. (C) Tumor weight of control or LINC00261-silenced PC-3 tumors upon harvest at day 32 after
implantation into mice (**P = 0.0043). (D) Representative IHC images and (E) quantification of PC-3 tumors from the control or LINC00261-
silenced arms stained for the proliferation marker Ki67. The scale bar at the bottom marks a 20 lm width. (A, C) Analyzed by unpaired two-
tailed t-test. (B) Analyzed by log-rank test: P = 0.018. (E) Images analyzed using IMAGEJ (see Materials and methods); statistically analyzed by
unpaired two-tailed t-test n = 15. All data are presented as mean  SEM with at least three independent biological replicates. ****P < 0.001.
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7 days of age. Notably, knockdown of FOXA2 dra-
matically attenuated the rate (Fig. S5D,E) and the
extent of metastatic dissemination (Fig. 4H,J) of PC-3
cells relative to the control group, which was compara-
bly phenocopied by the knockdown of LINC00261
alone. Altogether, these findings suggest that nuclear
upregulation of LINC00261 activates FOXA2 expres-
sion via chromatin recruitment of the SMAD2/3 com-
plex in NEPC cells, and FOXA2 in turn drives a gene
program of anchorage-independent survival and
growth at the metastatic site.
3.5. Cytoplasmic LINC00261 promotes
proliferation by regulating CXB2 expression
A predominant fraction of LINC00261 is retained in
the cytoplasm of PC-3 cells (Fig. 2B), where several
lncRNAs have been shown to function as a miRNA
sponge [34]. Thus, using publically available computa-
tional tools and miRNA databases, we explored
whether LINC00261 had binding sites for known miR-
NAs. Here, in many independent analyses, we found a
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Fig. 4. Nuclear LINC00261 promotes transcription of FOXA2 to drive invasion in NEPC cells. (A) Correlation between FOXA2 and
LINC00261 expression in transcriptomic data (RNA-seq) from prostate adenocarcinoma patients (TANRIC database; Spearman’s
correlation = 0.82). (B) Relative expression (microarray) of FOXA2 in several PDX models of prostate adenocarcinoma (n = 16) and NEPC
(n = 4) from the Living Tumor Laboratory (**P = 0.0050). (C) Relative expression (qPCR) of FOXA2 in FFPE biopsy samples from t NEPC
(n = 34) and CRPC-AD (n = 15) patients (Beltran et al. [16]; ****P < 0.0001). (D) FOXA2 expression (qPCR) in PC-3 cells transfected with a
nontargeting control (siControl) or siRNA targeting LINC00261 (**P = 0.0016). (E, top panel) Immunoblots showing FOXA2 protein
expression in PC-3 cells transfected with a nontargeting control (siControl) or siRNA targeting LINC00261 (HPRT1 serves as loading control).
(E, bottom panel) Expression of murine Foxa2 protein in NEPC OPT7714 cells transfected with a nontargeting control (siControl) or siRNA
targeting 9030622O22-Rik. (F) Relative quantification (qPCR) of U1, NS-lncRNA, and LINC00216 transcripts in RIP experiments using anti-
IgG or anti-SMAD2/3 antibody in PC-3 cells. (G) SMAD2/3 ChIP-seq peak profile plot averaged from 6724 binding sites in PC-3 cells treated
with either the nontargeting control siRNA (siNC) or siRNA targeting the LINC00261 (siLINC00261) gene. (H) The number of distinct
metastatic foci in the body of zebrafish embryos injected with PC-3-RFP cells with or without LINC00261 or FOXA2 knockdown
(P = 0.0146). (I) Representative images of zebrafish embryos from panel H. (B, C) Data Analyzed by two-tailed unpaired t-test. (B) Data
obtained from the living tumor laboratory. (C) RNA-seq data were obtained from the public database cBioPortal using the Trento NEPC
dataset. (D) Analyzed by two-tailed t-test. (F) Analyzed by one-way ANOVA with the Siddak post hoc test. (H) Analyzed by two-way ANOVA
with Dunnett’s post hoc test. All data are shown as mean  SEM and are from at least three biological replicates.
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miR-8485 within the 30 UTR of LINC00261 (top,
Fig. 5A). Thus, we set out to experimentally validate
the binding of miR-8485 to LINC00261 using the luci-
ferase reporter assay.
We aligned miR-8485 to the LINC00261 and
mapped the 100-bp segment in the 30 UTR centered at
the miRNA-binding site. We cloned this segment into
the 30 UTR of the firefly luciferase gene or cloned the
same segment without the 20bp miR-8485 seed region
to use as a negative control reporter. These reporter
vectors were co-transfected with a miR-8485 mimic or
a negative control miRNA in HEK293 cells, and the
luciferase reporter activity was measured. Here, we






















Fig. 5. Cytoplasmic LINC00261 buffers miR-8485 increasing CBX2 activity to drive proliferation in NEPC cells. (A, top) Computational
analyses predict miR-8485 binding within 30UTR of LINC00261. The partially complementary seed sequence is visualized below. (A, bottom)
Luciferase activity from the LINC00261-binding reporter assay with transfection of miR-8485 or a nontargeting control miRNA mimic in
HEK293 cells. For each treatment group, reporter activity was normalized to background signals from the unmodified pmirGlo reporter
alone. (B) Overlap between predictive targets of miR-8485 (n = 7742) and differentially expressed genes (DEGs; n = 179) in LINC00261-
silenced PC-3 cells (RNA-seq). 77 gene candidates were common in the two lists with top 10 genes shown. (C) CBX2 expression (qPCR) in
PC-3 cells treated with a nontargeting control (siControl) or siRNA targeting LINC00261 (***P = 0.0002; ****P < 0.0001) or (D) treated with
miR-8485 or nontargeting miRNA mimic (*P = 0.0434). (E) Viability (MTT assay) of PC-3 cells treated with a negative control mimic (NC
mimic) or miR-8485 mimic (****P < 0.0001). (F) Heat map showing mRNA expression (RNA-seq) changes in CBX2 target genes in PC-3
cells treated with siLINC00261 or siNC. (A, B) Analyzed by two-tailed t-test n = 6. (D) Analyzed by one-way ANOVA with Dunnett’s
post hoc test n = 2. (E) Analyzed by two-tailed t-test n = 3. (F) Analyzed by two-way ANOVA with Tukey’s post hoc test n = 6. All data are
shown as mean  SEM.
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reduction in reporter activity relative to cells treated
with the control miRNA (bottom, Fig. 5A). As
expected, this regulation was completely abolished for
the control reporter where the 20bp miR-8485 seed
region was deleted (Fig. S6A). This raised a pertinent
question: Which gene targets of miR-8485 are buffered
by the LINC00261 transcript? To address this, using
RNA-seq we profiled transcriptomic changes upon
LINC00261 knockdown in PC-3 cells (Table S3) and
overlapped the differentially expressed gene list with
computationally predicted targets of miR-8485 (see
Materials and methods). This identified 77 distinct
genes, which notably included a known epigenetic dri-
ver of NEPC called CBX2 (Fig. 5B, Table S4; [35,36]).
Notably, knockdown of LINC00261 led to a dramatic
reduction in CBX2 expression (Fig 5C). Consistently,
the overexpression of miR-8485 reduced the expression
of CBX2, while exogenous overexpression of an anti-
sense miR-8485 inhibitor increased the expression of
the CBX2 transcript (Fig. 5D, Fig. S6B). Long-term
treatment with the miR-8485 mimic also led to a sig-
nificant inhibition of cell proliferation in PC-3 cells
(Fig. 5E). Next, to assess transcriptional activity of
CBX2 in LINC00261-silenced PC-3 cells, we profiled
changes in the expression of CBX2 target genes previ-
ously identified in this study [36]. We found a dra-
matic concordance between siLINC00261 and siCBX2
gene signatures, with several CBX2 upregulated genes
being downregulated upon LINC00261 knockdown
and vice versa (Fig. 5F). Furthermore, we corrobo-
rated that miR-8485 levels were reduced in NEPC
using the LTL313 xenograft model upon castration
(Fig. S6C) and confirmed CBX2 expression was
increased in metastatic advanced PCa tissue with
NEPC features (Fig. S6D). Altogether, these findings
show that the cytoplasmic fraction of LINC00261
binds to and sequesters miR-8485, which otherwise
inhibits CBX2 activity and thereby proliferation in
NEPC cells.
4. Discussion
Neuroendocrine prostate cancer is a universally fatal
variant of PCa due to its late diagnosis, treatment
resistance, and metastatic capability. Hence, new ther-
apeutic approaches are urgently needed for this dis-
ease. Given increasing evidence implicating lncRNAs
in cancer biology, we hypothesized that the highly con-
served lncRNAs may play a role in the initiation and
progression of NEPC. Identification of lncRNAs rele-
vant for NEPC may provide an untapped resource of
potential therapeutic targets in the fight against this
rapidly fatal disease. Previous studies have used
bioinformatics [37] or candidate gene approaches [38]
to explore the noncoding transcriptome of NEPC. In
this study, we conducted an unbiased, whole-transcrip-
tome analysis, which allowed us to identify and func-
tionally characterize LINC00261, a highly conserved
lncRNA that drives NEPC proliferation and survival.
Evolutionarily conserved lncRNAs are often impli-
cated in fundamental cellular functions and control the
neoplastic transformation of different tissues and
organisms [13]. This paradigm is corroborated by the
second most conserved lncRNA in our list, MIAT.
MIAT is known to be expressed in NEPCs and is cor-
related with poor prognosis, high metastatic potential,
and frequent Rb mutations [39]. Notably, MIAT’s
oncogenic role has been confirmed in other malignan-
cies [40], and this lncRNA plays disparate roles in neu-
ral tissue specification [41] and vascular remodeling
[42].
Our results, as well as data from independent data-
bases, confirmed that LINC00261 is highly upregulated
in clinical NEPC samples. Our analyses also revealed
that LINC00261 expression is negatively correlated
with AR amplification in clinical samples and is
restricted to AR-negative preclinical models; this sug-
gested that this LINC00261 is crucial for the survival
of androgen-indifferent cells. This hypothesis was cor-
roborated by our in vitro and in vivo experiments on
cell proliferation and tumor cell metastasis. Recent
studies indicate that androgen-indifferent PCas often
activate several alternative survival pathways [43]. This
paradigm is in agreement with the positive correlation
between AKT2 amplification and LINC00261 expres-
sion in PCa clinical samples.
Notably, LINC00261 is also upregulated in hepatic
metastases from prostate adenocarcinomas. This obser-
vation could be explained by the fact that the hepatic
micro-environment promotes the neuroendocrine dif-
ferentiation of PCa cells [23,44]. Since liver metastases
are associated with a particularly dismal prognosis
[23], our findings further emphasize the clinical rele-
vance of LINC00261.
It has been previously shown that LINC00261
recruits SMAD2/3 to the promoter of FOXA2, thereby
inducing its transcription in normal cells [30]. Here, we
have shown that LINC00261 directly binds to and
recruits the SMAD2/3 complex to cis-regulatory ele-
ments of FOXA2, thereby upregulating FOXA2
expression in neuroendocrine-like PCa cells. Notably,
in the genomic space FOXA2 and LINC00261 are
coded in immediate genomic proximity of each other
and are co-expressed across cell lineages, raising an
intriguing possibility of functionally related lncRNA
and protein-coding gene pairs to show a higher degree
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of synteny through evolution. FOXA2 is a pioneer
transcription factor, which is able to bind compacted
chromatin and make it accessible for transcription
[45]. FOXA2 had been reported as a selective marker
for NEPC [46], but its role in metastasis and molecular
interactions in this context have not been fully eluci-
dated. Interestingly, we have previously shown that
global alterations of the chromatin structure underpin
the transdifferentiation from prostatic adenocarcinoma
to NEPC [7]. Based on our findings and on previous
evidence, it is conceivable that FOXA2 plays a pivotal
role in the chromatin remodeling of NEPC cells.
FOXA2 has also been shown to promote the recruit-
ment of p300 to transactivate hypoxia-inducible factor
(HIF)—regulated genes, which are highly expressed by
metastatic PCa. These genes are required for the for-
mation of NEPCs in siah2-null TRAMP mouse mod-
els [47]. Our in vivo data indicate that LINC00261
upregulation precedes FOXA2 expression during the
transdifferentiation process and that this event is fol-
lowed by the activation of the FOXA2 transcriptional
program. Notably, at least two of the FOXA2 tran-
scriptional targets identified by our analysis (ANK2
and RAB3C; Fig. S4C) are known to promote cancer
progression and metastasis [48,49].
CBX2 is one of the most highly upregulated epige-
netic modifiers in the neuroendocrine disease and in
cancer cells is required for cellular proliferation
[35,36,50]. Our findings reveal a novel miR-8485/CBX2
regulatory axis in PC-3 cells and show that
LINC00261 directly binds to and sequesters miR-8485
(i.e., works as a miRNA sponge), thereby increasing
CBX2 activity that fuels the growth of NEPC. Past
studies have shown CBX2 activity in cancer to be reg-
ulated by miRNAs [51], and to this list, we add a
novel candidate miR-8485 from PCa cells. There could
be other oncogenic targets of miR-8485 in NEPC, and
future studies are needed to uncover these genes and
their role in disease biology.
5. Conclusions
In summary, we identify a highly conserved
LINC00261 to be centrally involved in NEPC patho-
genesis by directly upregulating the expression of
CBX2 and FOXA2, which independently function as
key epigenetic drivers of hyperproliferation and metas-
tasis, respectively. Most importantly, we delineate two
distinct, cellular compartment-specific roles of
LINC00261. In the nucleus, LINC00261 acts as a tran-
scriptional scaffold to recruit the SMAD transcrip-
tional machinery at the FOXA2 cis-regulatory
elements, while in the cytoplasm, LINC00261 binds to
and sequesters miR-8485 that targets CBX2 (Fig. 6).
While no lncRNA-targeting drug has been approved
so far, recent reports indicate that antisense oligonu-
cleotides (ASOs) targeting oncogenic lncRNAs are
effective anticancer agents in vivo [52]. Notably, ASOs
Fig. 6. Cell compartment-specific
oncogenic functions of LINC00261. Inside
the nucleus, LINC00261 functions as a
transcriptional scaffold and recruits the
SMAD2/3 transcriptional machinery to the
FOXA2 cis-regulatory elements, thereby
increasing the FOXA2-driven anchorage-
independent growth and metastatic gene
programs. In the cytoplasm, LINC00261
sequesters the miR-8485:RISC complex
to block its binding with the CBX2
transcript, thereby increasing the CBX2-
driven proliferative gene program. Thus,
LINC00261 orchestrates neuroendocrine
trans-differentiation in PCa by regulating
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are in clinical trials for the treatment of several
pathologies [53]. Hence, LINC00261 may represent an
attractive therapeutic target against metastatic NEPC
and could provide a novel route to inhibit disease-driv-
ing chromatin modifiers that are currently considered
undruggable.
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Fig. S1. LncRNAs up-regulated in the PDX LTL-
331R, ranked by evolutionary conservation in 17 spe-
cies. (A) Workflow for lncRNA identification. Tran-
scripts were identified by RNA-seq of the patient-
derived xenograft (PDX) models LTL-331 (prostatic
adenocarcinoma) and LTL-331R (NEPC). lncRNA
reads were shortlisted with the criteria log2 fold change
< 4; false-discovery rate < 0.1; fragments per kilo-
base of transcript per million mapped reads-FPKM
> 10. (B) Ranked shortlist of lncRNAs ordered by
number of species with orthologs in Hezroni et al.,
2015. NEPC Associated lncRNAs (NEARs) were then
assigned numbers based on their rank in this shortlist.
Fig. S2. Subcellular localization of murine ortholog
9030622O22-Rik and essentiality of LINC00261 in
NEPC. (A) The expression of LINC00261’s murine
ortholog 9030622O22-Rik in T23 (murine prostatic
adenocarcinoma) and OPT7714 (murine NEPC). (B)
Subcellular localization of Gapdh, Malat1, and
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9030622O22-Rik RNA transcripts in OPT7714 cells.
(C) Expression of LINC00261 after treatment with
LINC00261-targeting siRNAs in PC-3 cells (siRNA
No. 1 P < 0.0001 siRNA No. 2 P < 0.0001, siRNA
No. 3 P < 0.0001, all relative to siNC treated cells).
(D) Representative images of PC-3 cells 72 h after
transfection with siNC or siLINC00261 (E) Viable PC-
3 cell counts after treatment with a control siRNA or
three different siLINC00261 for 3 days. (F) Viable
DU-145 cells 7 days after treatment with negative con-
trol empty vector (NC) or LINC00261 overexpression
vector (overexpression-OE; **P = 0.0030). (A, B) data
n = 3,  SEM, Analyzed by GRAPHPAD PRISM 7 soft-
ware. (C) Analyzed by one-way ANOVA with Dun-
nett’s post hoc test. (E) Analyzed by unpaired two-
tailed t-test (n = 2). All data Analyzed using GRAPHPAD
PRISM 7 software, n = 3  SEM unless otherwise sta-
ted.
Fig. S3. Effects of LINC00261 on metastatic cellular
properties. (A) LINC00261 expression (qPCR) in PC-3
cells at 18 h post transfection with a nontargeting con-
trol (siControl) or siRNAs targeting LINC00261. (B)
Viability (MTT assay) in PC-3 cells 18 h post treatment
with a negative control mimic (NC mimic) or distinct
siRNA targeting LINC00261. (C) Rate of wound heal-
ing in PC-3 cells with or without LINC00261 knock-
down. (D) Representative wound-healing images taken
at 0, 8, and 24 h (PC-3 cells). (A, B) Analyzed by one-
way ANOVA with Dunnett’s multiple comparisons
test. All statistical analysis Analyzed using GRAPHPAD
PRISM 7 software, n = 3  SEM.
Fig. S4. FOXA2 expression and activity is associated
with NEPC. (A) Expression (qPCR) of LINC00261 in
the NEPC PDX mode LTL-331Rl and a panel of non-
neoplastic tissues (****P < 0.0001). Numbers above
bars represent the number of samples pooled. (B)
Expression (qPCR) of FOXA2 in the NEPC PDX
model LTL-331R and a panel of non-neoplastic tissues
(****P < 0.0001). Numbers above bars represent the
number of samples pooled. (C) Expression of FOXA2
in clinical samples of secondary PCa lesions from pri-
mary site/lymph nodes (n = 53), bone (n = 29) or liver
(n = 17) (****P < 0.0001, ANOVA and Tukey
post hoc test). Data from cBioPortal, Metastatic PCa
SU2C/PCF Dream Team Cell 2015 (D) Time-lapse
expression of LINC00261 and FOXA2 (RNA-seq) in
the LTL-331/331R PDX models post-Cx: postcastra-
tion. (E) Heat map showing expression changes in the
AR and FOXA2 transcriptional programs in the
LTL331/331R NE trans-differentiation PDX models.
Top panel - AR signaling targets are up-regulated in
LTL-331; middle panel- NE markers are up-regulated
in LTL-331R; bottom panel FOXA2 transcriptional
targets (validated using www.amp.pharm.mssm.edu)
are up-regulated in LTL-331R. Data obtained from
RNA-seq data of three individual samples for each
LTL model. Blue tones lower expression; red tones
higher expression. (A–C) Analyzed by one-way
ANOVA with Dunnett’s post hoc test (*P = 0.0277).
RNA-seq data were obtained from the public database
cBioPortal using the Trento NEPC dataset. (E) Data
visualized by Microsoft excel. All data  SEM except
E (min to max). All statistical analysis Analyzed using
GRAPHPAD PRISM 7 software.
Fig. S5. LINC00261 knockdown attenuates SMAD2/3
chromatin binding and hinders anchorage-independent
growth and metastatic ability of PC-3 cells. (A) Top,
Normalized SMAD2/3 ChIP-seq read densities at all
of its genomic binding sites (n = 6724) in PC-3 cells
or, bottom, cis-regulatory genomic sites within the
4Mb window centered at the FOXA2 gene (n = 10).
(B) SMAD2/3 ChIP-seq read density tracks from siNC
or siLINC00261-treated PC-3 cells at distinct genomic
loci encoding bona fide TGF-b1/SMAD target genes.
(C) Left, Representative images of iodonitrotetra-
zolium chloride stained soft agar PC-3 cell colonies
after treatment with either the nontargeting, control
siRNA (siNC) or siRNA targeting the LINC00261
(siLINC00261) transcript (two-tailed t-test). Insets at
the bottom show magnified images of the colonies.
Right, Average number of soft agar colonies per 109
field of siNC or siLINC00261-treated PC-3 cells. Dis-
tinct cells colonies were counted from three randomly
chosen 10X field per well from two biological repli-
cates. (D) Expression (qPCR) of LINC00261 and
FOXA2 in siRNA-treated PC-3-RFP cells used for the
in zebrafish metastasis experiments. (E) Percentage of
fish that show metastatic dissemination at 1 and
2 days after injection with PC-3-RFP cell treated with
a nontargeting control (siControl; n = 52), siRNA tar-
geting LINC00261 (n = 40), or siRNA targeting
FOXA2 (n = 44). (A, D) was statistically analyzed
using two-tailed t-test and (C) was analyzed using a
one-way ANOVA with Dunnett’s post hoc test.
Fig. S6. miR-8485 mimic downregulates the expression
of CBX2 to enable NEPC progression. (A) Luciferase
activity from the control, mutated LINC00261 binding
reporter assay (see Materials and methods) with trans-
fection of miR-8485 or a nontargeting control miRNA
mimic in HEK293 cells. For each treatment group,
reporter activity was normalized to background signals
from the unmodified pmirGlo reporter alone. (B)
Expression of CBX2 is significantly reduced upon
expression of miR-8485 mimic compared to mimic
control. Expression of CBX2 is significantly increased
upon miR-8485 inhibition compared to inhibitor
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control. (C) Expression of has-miR-8485 in CRPC-
Adeno (n = 13) or NEPC (n = 4) patient-derived PCa
xenografts that are hormone-sensitive or hormone-re-
sistant. (D) Expression of CBX2 in PCa patient sam-
ples with (n = 15) or without (n = 34) presentation of
NEPC features. (B) Data analyzed by unpaired two-
tailed t-test (*P < 0.05).
Table S1. LINC00261 is associated with NEPC mark-
ers and FOXA2. Using co-expression analysis on
cBioPortal accessed from the Trento dataset
LINC00261 expression has a tendency towards co-oc-
currence with FOXA2, and the NEPC markers ENO2,
CHGA, CBX5 and NCAM1 expression. There is also a
tendency towards co-occurrence between FOXA2 and
the markers ENO2, CHGA, CBX5 and NCAM1.
Table S2. LINC00261 survival data from all other can-
cers available on the TANRIC database with the top
correlated mRNA in each dataset. Using the TANRIC
database each cancer type was queried for LINC00261
expression correlated with survival, and with mRNA.
Only the top Spearman score mRNA is shown per
dataset. Numbers of clinical samples in each data set
is shown.
Table S3. List of differentially expressed genes (RNA-
seq) in siLINC00261-treated PC-3 cells. RNA-seq
analysis was carried out using criteria described in
Materials and methods section. In total, the analyses
revealed 180 down-regulated transcripts, and 519 up-
regulated transcripts upon LINC00261 knock-down.
Table S4. Common genes between the predicted miR-
8485 targets and genes down-regulated upon
LINC00261 silencing in PC-3 cells. For each of the 77
genes, fold change and associated P-value upon
LINC00261 silencing are shown, along with identifica-
tion of the miRNA-binding tools that predict targeting
by miR-8485.
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